Table 3 |
|||||
|
Systematic reviews on Vitamin D for prevention or treatment (in chronological order) |
|||||
|
Area |
Number of studies |
Type |
Doses |
Conclusion |
Reference |
|
|
|||||
|
Cardiovascular events |
17 |
Prospective |
~1000IU |
S not SS |
162 |
|
|
|||||
|
Cardiometabolic outcomes |
31 |
Observ/Trial |
Range |
No effect |
163 |
|
|
|||||
|
Fracture prevention |
7 |
Randomised |
10-20 mcg + Ca |
No effect Reduced risk |
164 164 |
|
|
|||||
|
Physical performance |
8 8 |
Observational Intervention |
- - |
Positive (5/8) Mixed |
165 165 |
|
|
|||||
|
Kidney disease (-dialysis) |
16 |
RCT |
- |
Uncertain |
166 |
|
|
|||||
|
Kidney disease (+dialysis) |
60 |
RCT |
- |
Uncertain |
167 |
|
|
|||||
|
Cystic fibrosis |
3 |
(q)RCT |
800-1600IU |
No effect |
168 |
|
|
|||||
|
Risk of falling |
8 |
RCT |
700-1000IU 200-600IU |
Reduced risk No effect |
169 169 |
|
|
|||||
|
Hypertension |
11 |
RCT |
- |
S - SS |
170 |
|
|
|||||
|
Risk of falling |
111* |
RT or interv. |
- |
No effect |
171 |
|
|
|||||
|
Fracture prevention |
45 |
(q)RCT |
- +Ca |
No effect S not SS |
172 172 |
|
|
|||||
|
Risk of Type 1 diabetes |
5 |
Observational |
- |
Uncertain |
136 |
|
|
|||||
|
Parathyroid hormone |
52 |
Intervention |
_ |
Decrease |
173 |
|
|
|||||
|
Mortality |
18 |
RCT |
2300-2000IU |
Uncertain |
174 |
|
|
|||||
|
Risk of fall/fracture |
9 |
- |
- |
Decrease (trend) |
175 |
|
|
|||||
|
Risk of fracture |
12 |
RCT |
700-800IU 400IU |
Decrease (trend) No effect |
176 176 |
|
|
|||||
|
Risk of fall |
10 |
RCT |
- |
Decrease |
177 |
|
|
|||||
|
Bone density Fracture |
17 17 |
RCT RCT |
- - |
Uncertain Reduction |
178 |
|
|
|||||
|
S not SS: Small effect - not statistically significant (sub-groups are discounted); RCT: Randomised controlled trial {(q) - quasi}; * Multiple factor study. |
|||||
|
Zhang and Naughton Nutrition Journal 2010 9:65 doi:10.1186/1475-2891-9-65 |
|||||
